BioCryst Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

BioCryst Pharmaceuticals

02/11/2023 13:32

* BioCryst Pharmaceuticals Inc  BCRX.OQ  reported a
quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -23 cents.  The mean expectation of
ten analysts for the quarter was for a loss of 23 cents per
share. Wall Street expected results to range from -41 cents
to -12 cents per share.
    * Revenue rose 14.4% to $86.74 million from a year ago;
analysts
expected $85.95 million. 
    * BioCryst Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 19 cents​.
    * The company reported a quarterly loss of $36.15 million.
    * BioCryst Pharmaceuticals Inc shares had fallen by 19.1%
this
quarter and lost 50.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.50 
This summary was machine generated from LSEG data November 2 at
01:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.23          -0.19          Beat
 Jun. 30 2023      -0.23          -0.24          Missed
 Mar. 31 2023      -0.30          -0.28          Beat
 Dec. 31 2022      -0.17          -0.38          Missed